Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir/rilpivirine.

Autor:	Alagaratnam J; Department of HIV Medicine & Sexual Health, Chelsea & Westminster Hospital NHS Foundation Trust.; Section of Virology, Department of Infectious Disease, Faculty of Medicine, Imperial College London., Kelly N; Section of Virology, Department of Infectious Disease, Faculty of Medicine, Imperial College London., Dustan S; Section of Virology, Department of Infectious Disease, Faculty of Medicine, Imperial College London., Naous N; Department of HIV Medicine & Sexual Health, Chelsea & Westminster Hospital NHS Foundation Trust., Nwanbila M; Department of HIV Medicine & Sexual Health, Chelsea & Westminster Hospital NHS Foundation Trust., Byrne R; Department of HIV Medicine & Sexual Health, Chelsea & Westminster Hospital NHS Foundation Trust., Girometti N; Department of HIV Medicine & Sexual Health, Chelsea & Westminster Hospital NHS Foundation Trust., Asboe D; Department of HIV Medicine & Sexual Health, Chelsea & Westminster Hospital NHS Foundation Trust., Taylor GP; Section of Virology, Department of Infectious Disease, Faculty of Medicine, Imperial College London.; National Centre for Human Retrovirology, Imperial College Healthcare NHS Trust, London, UK., Boffito M; Department of HIV Medicine & Sexual Health, Chelsea & Westminster Hospital NHS Foundation Trust.; Section of Virology, Department of Infectious Disease, Faculty of Medicine, Imperial College London.
Jazyk:	angličtina
Zdroj:	AIDS (London, England) [AIDS] 2025 Jan 01; Vol. 39 (1), pp. 95-98. Date of Electronic Publication: 2024 Dec 05.
DOI:	10.1097/QAD.0000000000004040
Abstrakt:	Increasingly, people attending HIV services are requesting long-acting injectable (LAI) antiretroviral treatment (ART). However, without HIV RNA resistance-associated mutation results, individuals are considered unsuitable for LAI ART. We present our experience of sequencing proviral HIV DNA in 30 individuals to inform suitability for LAI ART, of whom 23 were considered suitable. In conclusion, optimization of diagnostic tools such as proviral HIV DNA sequencing to confirm suitability for LAI ART would be a welcome addition. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu